IntelGenx Announces Issuance of New U.S. Patent Covering VersaFilm® Technology
SAINT LAURENT, Quebec, Oct. 20, 2022 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx"), a leader in pharmaceutical...
Pharmaceutical
Amarin to Report Third Quarter 2022 Financial Results And Host Conference Call on October 27, 2022
DUBLIN, Ireland and BRIDGEWATER, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will...
HMNC Brain Health Raises EUR 14.3 million to Advance Precision Psychiatry Therapies
Round Comprised of New and Former Investors, Including Dr. Josef Ackermann, Wilhelm Beier, Toni Kroos, and Carsten Maschmeyer First of...
Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022
STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced...
X4 Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host a Conference Call and Webcast to Discuss Important Upcoming Milestones on November 3, 2022
BOSTON, Oct. 20, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of...
T-knife Therapeutics Announces Dosing of First Patient with TK-8001 in the IMAG1NE Phase 1/2 Clinical Trial
The IMAG1NE Phase 1/2 trial is an accelerated dose-titration, open-label, multi-center Phase 1/2 trial to evaluate TK-8001 in patients with...
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
“Potential Early Intervention with an Oral Treatment for Stargardt Disease and Dry Age-Related Macular Degeneration” Thursday, October 27th at 11...
Sunshine Biopharma Announces the Acquisition of Nora Pharma, Adding $10.7 Million in Revenue
MONTREAL, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company focused on the research, development...
Kala Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals,...
Iterum Announces First Patient Dosed in REASSURE, a Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections
-- NDA resubmission expected in Second Half of 2024, if successful-- --Oral sulopenem, if approved, could be the first antibiotic...
Avicanna Files Complete Patent Specifications Relating to a Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy
Recent in-vivo studies conducted in partnership with the University of Toronto confirm Formulation Candidate’s anti-seizure properties allowing for formalization of...
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
Company also presenting at upcoming investor conferencesWATERTOWN, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a...
PolyPid Announces Cost Reduction Plan
Reduction of Approximately 20% in Organization Headcount Company Expects to Extend Cash Runway into Q3 2023 PolyPid Intends to Discuss...
Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing...
HOOKIPA announces strategic collaboration and license agreement with Roche to develop novel arenaviral immunotherapy for KRAS-mutated cancers
Roche to receive license for HOOKIPA’s HB-700 program and option to license a second undisclosed novel arenaviral immunotherapyHOOKIPA to receive...
Agios to Webcast Conference Call of Third Quarter 2022 Financial Results on November 3, 2022
CAMBRIDGE, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular...
Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults
AUVELITY is the first and only rapid-acting oral treatment approved with labeling of statistically significant improvement in depressive symptoms compared...
Societal CDMO Announces Signing of Multiple New CDMO Service Agreements
Agreements Showcase Company’s Ability to Support Novel Therapeutic Programs Regardless of Development Stage; Services Focused on Both Preclinical and Last...
Telesis Bio and Cellibre Announce Collaboration to Optimize Development of Future BioXp® DBC instrument
Agreement will allow researchers to streamline development of on-demand and automated production of CRISPR-Cas9 guide RNASAN DIEGO, Oct. 19, 2022...
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices Conference
Further Demonstrating Possibilities for Systemic Delivery of Large MoleculesSAN DIEGO, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq:...